Company Profile

Ionis Pharmaceuticals Inc (AKA: ISIS Pharmaceuticals Inc)
Profile last edited on: 11/2/22      CAGE: 09HU6      UEI: P8PVTLSDNNS6

Business Identifier: RNA-targeted drug discovery
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2855 Gazelle Court
Carlsbad, CA 92010
   (760) 931-9200
Location: Single
Congr. District: 49
County: San Diego

Public Profile

Originally doing business as ISIS Pharmaceuticals, Inc., in December 2015 the firm changed its name and symbol to Ionis Pharmaceuticals (IONS). The firm is engaged in the discovery and development of a new class of drugs based on antisense technology - a novel a RNA-targeted drug discovery platform focused on treating cardiovascular, metabolic and severe neurodegenerative diseases, and cancer for systemic, local, and inhaled delivery. The company has commercialized antisense drugs and has a large number of other drugs in development. Focused on developing drugs for patients with severe and rare diseases, the firm markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia. Drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; and nusinersen, a drug for the treatment of infants and children with spinal muscular atrophy. Ionis is also developing Custirsen, which is in two Phase III studies to treat cancer; and Plazomicin that is Phase III study for the treatment of severe bacterial infection. The firm's flagship product, Vitravene inhibits cells from producing disease-causing proteins, the drug treats cytomegalovirus retinitis, a cause of blindness in AIDS patients. Partner Novartis Ophthalmics (a unit of Novartis) sells the drug worldwide. Isis has other antisense-based drugs in various stages of development. Lead drug candidate Alicaforsen could help people suffering from ulcerative colitis, or inflammation of the colon. Other drug candidates target diabetes, elevated cholesterol levels, multiple sclerosis, and cancer. The firm has an extensive list of working relationships and collbaorations with major and mid-sized corporations. In 2008, Abbott acquired that part of Isis Pharmaceuticals' dba Ibis Biosciences

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 2 NIH $1,487,371
Project Title: Chemical Modification to Improve siRNA Pharmacokinetics in Animals
2008 2 NIH $432,275
Project Title: Identification of an inhibitor of microRNA-122 in liver
2006 2 Army $848,085
Project Title: TIGER Biosensor for Broad Viral Detection and Genetically Engineered Microbes
2002 2 NIH $850,000
Project Title: L11/23s Rrna Interaction--Antimicrobial Drug Development
2001 1 NIH $100,000
Project Title: Combinatorial Carbohydrate Libraries for Drug Discovery

Key People / Management

  Stanley T Crooke -- CEO

  Brenda F Baker

  Lawrence B Blyn

  Lex M Cowsert

  Rosanne M Crooke

  NIcholas Dean

  Kenneth G Draper

  Susan M Freier

  Jane Green -- Dir. Corp. Communications

  Richard H Griffey

  Glenn D Hoke

  Muthiah Manoharan

  John McNeil

  Christopher K Mirabelli -- Founder

  LeeAnne Patton

  Ray Ranken

  Daniel Ripley -- Founder

  Rangarajan Sampath

  Kevin Skol -- Business Development

  Eric E Swayze

  Jacqueline R Wyatt